In Brief: Diolase
This article was originally published in The Gray Sheet
Diolase: Submits corrective action plan and variance request in response to May 23 FDA warning letter for the Diolase Model 100 Therapeutic Laser. The laser, used in the relief of head, neck, jaw and upper back pain, was cited for several issues including labeling, its lack of a remote interlock connector, lack of a "adequate emission delay" and lack of procedures and schedule for recalibration of the system. Diolase's variance request for the device's inadequate emission delay explains that the laser incorporates the ShortStop proximity sensor, which serves to prevent accidental laser beam emission...
You may also be interested in...
Interview: recently appointed CEO Richard Francis will apply his background in big pharma and biotech to building the UK start-up Purespring Therapeutics with a focus on using gene therapy technology to target renal diseases.
Sandoz Canada has become the first manufacturer to launch generic versions of posaconazole and silodosin in Canada. The company launched the generic version of Allergan’s Rapaflo (silodosin) after a Canadian court ruled that Sandoz did not infringe a key formulation patent.
US healthcare insurance provider Health Net failed to respect Amarin’s patent rights in the way it distributed Hikma’s generic version of Vascepa (icosapent ethyl), the originator contends in an expanded induced infringement suit.